SB2499

AN ACT to amend Tennessee Code Annotated, Title 4; Title 56 and Title 71, relative to the coverage of long-acting injectable drugs for the treatment or prevention of human immunodeficiency virus.

Introduced·2/2/26

Tennessee SB2499 amends state law to require reimbursement for long-acting injectable drugs for HIV treatment and prevention.

Tennessee SB2499 amends Tennessee Code Annotated, Title 71, to require managed care organizations (MCO) and pharmacy benefits managers (PBM) to reimburse claims for long-acting injectable drugs intended for the treatment and prevention of human immunodeficiency virus (HIV). These drugs must be administered in a pharmacy, physician's office, clinic, ambulatory surgical treatment center, or hospital. The act also mandates that if an MCO or PBM covers such a claim as a medical benefit or service, it must also cover it as a pharmacy benefit. This change takes effect July 1, 2026.

Included in complete analysis

  • Overview
  • Core Provisions
  • Implementation
  • Impact
  • Legal Framework
  • Critical Issues

See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.

Where it stands

Current
Commerce and Labor Committee
Next
Committee decision

Sponsors

D
1
0
Democratic CaucusRepublican Caucus

Calendar

Mar 10

3:00 PM

Senate Commerce And Labor Hearing

History

Mar 10

Senate

Assigned to General Subcommittee of Senate Commerce and Labor Committee

Mar 5

Senate

Passed on Second Consideration, refer to Senate Commerce and Labor Committee

Mar 4

Senate

Placed on Senate Commerce and Labor Committee calendar for 3/10/2026